Integra LifeSciences Holdings Corporation (NASDAQ:IART – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $14.05 and traded as high as $16.94. Integra LifeSciences shares last traded at $16.74, with a volume of 551,041 shares.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on IART shares. Citigroup reiterated a “neutral” rating and set a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Wall Street Zen cut shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Thursday, June 18th. Finally, UBS Group initiated coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price objective on the stock. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $18.86.
Check Out Our Latest Research Report on Integra LifeSciences
Integra LifeSciences Trading Up 0.9%
Integra LifeSciences (NASDAQ:IART – Get Free Report) last issued its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The company had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, analysts forecast that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current year.
Hedge Funds Weigh In On Integra LifeSciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC acquired a new stake in shares of Integra LifeSciences in the 4th quarter valued at approximately $879,000. Tejara Capital Ltd boosted its stake in Integra LifeSciences by 42.6% during the 4th quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after acquiring an additional 51,300 shares during the last quarter. UBS Group AG grew its holdings in Integra LifeSciences by 211.7% during the fourth quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock valued at $5,079,000 after purchasing an additional 277,745 shares during the period. Glenmede Trust Co. NA increased its stake in Integra LifeSciences by 27.4% in the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after purchasing an additional 211,774 shares in the last quarter. Finally, Systematic Financial Management LP raised its holdings in Integra LifeSciences by 4.5% in the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock worth $13,769,000 after purchasing an additional 48,094 shares during the period. Institutional investors own 84.78% of the company’s stock.
About Integra LifeSciences
Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.
Featured Stories
- Five stocks we like better than Integra LifeSciences
- Travel + Leisure Goes Big—Is It Ready to Rally?
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
